alexa Good Response To Infliximab In Rheumatoid Arthritis Following Failure Of Interleukin-1 Receptor Antagonist
ISSN: 2161-0533

Orthopedic & Muscular System: Current Research
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

2nd International Conference and Exhibition on Orthopedics & Rheumatology
August 19-21, 2013 Embassy Suites Las Vegas, NV, USA

Jun Bao
Accepted Abstracts: Orthop Muscul Syst
DOI: 10.4172/2161-0533.S1.014
I ntroduction: To evaluate the efficacy of tumor necrosis factor inhibitor infliximab in patients with rheumatoid arthritis (RA) who were disease resistant to recombinant humaninterleukin-1 receptor antagonist (IL-1Ra). Methods: A total of 104 patients with active RA despite methotrexate (MTX) therapy were enrolled. Among them, 27 patients who failed to respond to at least 3-month IL-1Ratreatment (?Switchers?) were assigned to an infusion of 3 mg/kg infliximab at weeks 0, 2, 6 and 14, combined with concurrent MTX therapy. The Other 77 patients who had never previously received any biologics were double-blindly randomized in a 2:1 ratio to receive infliximab (n=51, ?Naivers?) or placebo n=26, ?Controls?) plus MTX treatment. Clinical outcomes and safety were assessed at weeks 0, 2, and every 4 weeks thereafter for 18 weeks with the American College of Rheumatology (ACR) core set criteria, the disease activity score in 28 joints (DAS28), and the records of adverse events (AEs) and abnormal laboratory findings. Results: At week 18, an ACR20 response was achieved in 56% of switchers and 61% of naivers, compared with 23% of controls (P=0.0013 and 0.0126, respectively). Between the two infliximab-treated groups, naives had achieved an ACR20 response by week 2, earlier than switchers; but switchers achieved a greater benefit from HAQ score than naives. Infliximab was well tolerated, with a similar incidence of AEs, serious AEs and AEs leading to withdrawal across all study groups. However, more switchers developed infusion-related reactions, compared with the placebo group. Conclusion: Switching from IL-1Rato infliximab is effective in improving disease activity and maintaining joint function obtained with IL-1Ra.Caution for infusion-related reactions should be required during switching treatment of RA.
image PDF   |   image HTML
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version